| Today's Top Story |  |  | | | Health Care & Policy | | | | - Days of plenty are over for biomedical research
As NIH funding for biomedical research has dwindled, scientists are turning to big drugmakers and disease-focused foundations, shifting the focus from basic to translational research, writes Luke Timmerman. The result could be a slew of new drugs, devices and diagnostics over the next decade, he writes. But moving too far away from basic research could bring missed opportunities for "a whole series of bigger breakthroughs that can come only from asking basic, open-ended research questions about how genes, cells, and lower organisms work," he writes. Xconomy (12/31)       - Janssen, NGM team up to develop diabetes drugs
Janssen Pharmaceuticals and NGM Biopharmaceuticals agreed to collaborate in the discovery and development of drugs for metabolic disorders including type 2 diabetes. The partners specifically will seek to develop treatments that imitate bariatric surgery's glucoregulatory effects. Aside from upfront payment and research funding, NGM is entitled to possible milestone fees and royalties. Janssen will get the exclusive worldwide development, production and marketing rights to compounds emerging from the partnership. Genetic Engineering & Biotechnology News (1/3) - Philogen licenses autoimmune disease drug to Pfizer
Pfizer secured exclusive, worldwide rights to develop and market Philogen's Dekavil, an investigational drug for autoimmune diseases. Dekavil is an early-stage antibody that targets inflammatory disease sites. The deal entitles Philogen to an an upfront fee and potential milestone fees and royalties. Reuters (1/3) - Bayer-Onyx's Nexavar hits primary goal in thyroid cancer study
Bayer and Onyx Pharmaceuticals' Nexavar, or sorafenib, met the primary goal of a late-stage trial by significantly improving progression-free survival versus a placebo in patients with radioactive iodine therapy-resistant thyroid cancer. Bayer plans to submit Nexavar for regulatory approval as a treatment for radioactive iodine refractory differentiated thyroid cancer. The drug is cleared for liver and kidney cancer in more than 100 nations. Reuters (1/3), MedPage Today (free registration) (1/3) | Company & Financial News | | | | | Food & Agriculture | | | | | Industrial & Environmental | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Beware the fury of a patient man."
--John Dryden,
British poet, critic and playwright  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, January 03, 2013
- Wednesday, January 02, 2013
- Monday, December 31, 2012
- Friday, December 28, 2012
- Thursday, December 27, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment